Abstract: The present invention relates to a DNA expression cassette comprising the following sequence:5'-P-SP-LS-PS-*gene*-(T).sub.i -3'whereinP is a promoter sequence,SP is a DNA sequence encoding a signal peptide,LS is a DNA sequence encoding a leader peptide of formula I:GinProIle(Asp/Glu)(Asp/Glu)X.sup.1 (Glu/Asp)X.sup.2 AsnZ(Thr/Ser)X.sup.3 (SEQ ID NO: 77) (I)whereinX.sup.1 is a peptide bond or a codable amino acid;X.sup.2 is a peptide bond, a codable amino acid or a sequence of up to 4 codable amino acids which may be the same or different;Z is a codable amino acid except Pro; andX.sup.3 is a sequence of from 4 to 30 codable amino acids which may be the same or different;PS is a DNA sequence encoding a processing site;*gene* is a DNA sequence encoding a polypeptide;T is a terminator sequence; andi is 0 or 1.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 17, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Thomas B.o slashed.rglum Kjeldsen, Knud Vad
Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
June 17, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans Petersen, Knud Erik Andersen, Per Olaf S.o slashed.rensen, Jesper Lau, Behrend Friedrich Lundt
Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
June 3, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans Petersen, Knud E. Andersen, Per O. S.o slashed.rensen, Jesper Lau, Behrend F. Lundt
Abstract: This invention relates to enzymes, to rDNA techniques applicable for example to their production, to mutated genes, vectors and mutant and transformed microorganisms useful in their production, and to their uses including for example enzymatic detergent and cleaning compositions containing them.
Type:
Grant
Filed:
September 13, 1995
Date of Patent:
May 20, 1997
Assignees:
Novo Nordisk A/S, Unilever PLC
Inventors:
Sven Branner, Sven Hastrup, Nina Eriksen, Poul Lindegaard, Ole H. Olsen, Eric Casteleijn, Maarten R. Egmond, Johan Haverkamp, Wouter Musters, Jakob de Vlieg
Abstract: A process for the microbial production of a protein susceptible to inactivation in a fluid production medium by continuously and reversibly protecting said protein against said inactivation during the production stage, separating the protein from the production medium, deprotecting the protein, and recovering the protein product. The process is especially useful for obtaining substantially increased yields of the protein in question by continuously precipitating said protein.
Type:
Grant
Filed:
August 16, 1994
Date of Patent:
April 22, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Per L. Joergensen, Poul E. Pedersen, Joergen Petersen, Torben K. Nielsen, Jan M. Mikkelsen
Abstract: A process for hydrolysis of water-insoluble esters in the presence of a lipase, at a pH in the range of 3-7 particularly to such a process for hydrolysis of resin in pulp.
Type:
Grant
Filed:
November 10, 1994
Date of Patent:
April 1, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans P. Heldt-Hansen, Yuko Fujita, Haruo Awaji, Hidesato Shimoto, Masaki Sharyou
Abstract: This invention relates to lipase containing pharmaceutical compositions comprising a microbial, 1, 3-position specific, crystalline lipase and to methods for treatment or prophylaxis of lipase deficiency in mammals.
Abstract: The xylanase is characterized by several partial amino acid sequences and is immunoreactive with an antibody raised against a purified xylanase derived from Humicola insolens, DSM 1800. This xylanase preparation is practically free of cellulase xylanase and is well suited for treatment of paper pulp, as a baking agent and as an additive to fodder.
Type:
Grant
Filed:
September 21, 1993
Date of Patent:
March 11, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Martin Schulein, Torben Halkier, Hans P. Heldt-Hansen, Henrik Dalb.o slashed.ge, Lars S. Pedersen
Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
March 4, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans Petersen, Knud E. Andersen, Per O. S.o slashed.rensen, Jesper Lau, Henning B. Petersen, Behrend F. Lundt
Abstract: The transfer of a textile dye from a dyed fabric to another fabric during washing or rinsing is inhibited by adding an enzyme exhibiting peroxidase activity or an enzyme exhibiting a suitable oxidase activity to the wash liquor in which said fabrics are washed and/or rinsed. Peroxidase is produced extracellularly by some strains of Bacillus pumilus. The novel peroxidase preparation from B. pumilus is a microperoxidase, i.e. it contains hemopeptide as an active component. The preparation has improved stability at high temperature, at high pH and at high concentrations of hydrogen peroxide. It can be produced without undesired catalase activity.
Type:
Grant
Filed:
August 11, 1993
Date of Patent:
February 25, 1997
Assignees:
Novo Nordisk A/S, The Proctor & Gamble Company
Inventors:
Ture Damhus, Ole Kirk, Gitte Pedersen, Manuel G. Venegas
Abstract: The present invention relates to a process for preparing a triglyceride, comprising reacting glycerol with a polyunsaturated fatty acid having at least 20 carbon atoms and at least three double bonds or a C.sub.1-4 alkyl ester thereof, for a reaction time in the range of 24-48 hours at a temperature between 40.degree. and 80.degree. C. in the presence of a mixture of lipase A and lipase B obtained from Candida antarctica which is immobilized, to form (i) the triglyceride and (ii) water or a C.sub.1-4 alcohol, while removing the water or the C.sub.1-4 alcohol during the reaction, and recovering the triglyceride.
Type:
Grant
Filed:
January 23, 1995
Date of Patent:
February 18, 1997
Assignees:
Novo Nordisk A/S, LYSI HF
Inventors:
Gudmundur G. Haraldsson, Hanne Svanholm, Baldur Hjaltason
Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
February 18, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans Petersen, Knud E. Andersen, Per O. S.o slashed.rensen, Jesper Lau, Behrend F. Lundt
Abstract: The method for cleaning of heat exchangers after passage of fluid, pulpy material through the heat exchangers is characterized by the fact that the heat exchangers are exposed to a cip (cleaning in place) treatment with a solution of an enzyme preparation, which contains pectolytic, cellulolytic and hemicellulolytic activities. This method for cleaning of heat exchangers is less time and energy consuming and more environmental-friendly than the hitherto used methods of this kind.
Abstract: The present invention relates to a gene encoding an ascomycete or deuteromycete carboxypeptidase Y gene, and host cells modified so as to produce reduced amounts of carboxypeptidase.
Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, amino, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino;A is methyl, halomethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;R.sup.1 is selected from optionally substituted N-bonded heterocyclics.The compounds have been found useful for treating central nervous system ailments.
Abstract: The present invention relates to rhamnogalacturon acetyl esterases derived from Aspergillus aculeatus and DNA Sequences encoding the enzymes. The present invention also relates to the use of rhamnogalacturon acetyl esterases for degrading modified hairy region.
Type:
Grant
Filed:
October 5, 1994
Date of Patent:
December 17, 1996
Assignee:
Novo Nordisk A/S
Inventors:
Kurt Dorreich, Flemming M. Christensen, Yvette Schnell, Marcel Mischler, Henrik Dalb.o slashed.ge, Hans P. Heldt-Hansen
Abstract: This application relates to methods of treating myocardial or cerebral ischemia, comprising administering a compound of formula I: ##STR1## wherein X is halogen, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; andR.sup.1 is selected from N-bonded heterocycles.The compound with the greatest ability to discriminate between the A1 and A2 adenosine receptors is 2-chloro-N-[4-phenoxy-1-piperidinyl]adenosine.